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Background: This study investigated the status of diabetes control and management in patients treated in a
primary healthcare setting and compared the results with data previously obtained for secondary/tertiary
care patients in Taiwan.
Methods: This study was conducted at 51 primary healthcare stations randomly selected island-wide in Taiwan
in 2001. A total of 1302 type 2 diabetes patients who had been followed-up for more than 1 year were
included. Blood was collected for centralized HbA1c assay. The remaining data and information were collected
by review of medical records and patient interview.
Results: Compared with the results of a previous study on patients treated in a secondary/tertiary care
setting, a significantly smaller percentage of primary care patients were receiving insulin therapy. Primary
care patients also had a shorter duration of diabetes, a higher HbA1c level, better blood pressure control and
a lower prevalence of complications. The proportion of patients achieving optimal control of glycemia and
blood pressure was low. Patients aged < 65 years had a significantly shorter duration of diabetes, poorer
diabetes control and better blood pressure control than elderly patients aged * 65 years. Primary care patients
aged * 65 years had a significantly higher frequency of stroke than those aged < 65 years. The elderly group
of secondary/tertiary care patients had a significantly higher frequency of coronary heart disease and stroke.
Duration of diabetes and hypertension were the leading risk factors for complications in diabetes patients
treated in both primary and secondary/tertiary care settings.
Conclusion: Diabetes control was poorer in primary care than in secondary/tertiary care patients, but control
of blood pressure was better in primary care patients. The shorter duration of diabetes and better control of
blood pressure in primary care patients and in patients aged < 65 years compared with their elderly counterparts
might be related to a lower prevalence of complications. [J Formos Med Assoc 2006;105(2):105–117]
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Type 2 diabetes is a worldwide epidemic. Accord-
ing to projections by the World Health Organiza-
tion (WHO), the number of individuals with
diabetes will rise from 135 million in 1995 to 300
million in 2025,1 and much of the increase is ex-
pected to be experienced in Asia.2
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In Taiwan, diabetes is a major health problem
with an estimated 900,000 diabetic patients among
its 23 million inhabitants.3 Diabetes and its com-
plications represent a major threat to public health
resources, and the economic and societal costs of
managing this disorder and its complications are
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of a manpower shortage. Therefore, this study was
conducted in 51 primary healthcare stations (i.e.
medical care facilities where diabetic patients were
managed by general physicians) across four regions
in Taiwan from November to December in 2001.
These four regions referred respectively to north-
ern (Taipei, Taoyuan, Hsinchu and Miaoli
counties), central (Taichung, Nantou, Chuanghua
and Yulin counties), southern (Tainan, Kaohsiung
and Pingtung counties), and eastern (Ilan and Tai-
tung counties) Taiwan. Local working committees
comprising endocrinologists and diabetes opinion
leaders were responsible for patient recruitment
that would result in a study sample that was repre-
sentative of the diabetic population. In proportion
to the size of the local population in each region,
the numbers of the participating stations in
northern, central, southern and eastern Taiwan
were set at 19, 12, 14 and 6 respectively. Each par-
ticipating station provided data for patients who
had been followed-up regularly for more than 12
months at the station for diabetes management.
Data were collected on a retrospective-prospective
basis by reviewing patients’ medical records, as well
as through interviews with patients and laborato-
ry assessments. Due to incomplete data, 163 cases
out of 1502 eligible patients were excluded, result-
ing in an enrollment rate of 89.1%.
Data collection
The data collected on patients included demo-
graphic characteristics, type of diabetes, diabetes
management, frequency and types of interventions,
cardiovascular risk factors, renal function, glycemic
control in the previous 3 months, as well as eye,
foot, and other severe late complications experi-
enced in the previous 6 months. All data were re-
corded on data collection forms provided for each
patient.
Finger capillary blood samples were collected
from patients during their visits for central assess-
ment of glycosylated hemoglobin (HbA1c) using
the Bio-Rad HbA1c kit (Bio-Rad Diagnostic Group,
Hercules, CA, USA). All collected samples were
stored at 2–8°C and mailed in batches to the cen-
tral laboratory at the Diagnostic Department of the
expected to escalate along with their rising pre-
valence. Indeed, the annual incidence of diabetes
has reached 0.5–1% of Taiwan’s total population,
suggesting that there are at least 100,000 new
cases every year.3 Of greater concern has been the
sharp rise in the prevalence of diabetes among
Taiwanese citizens aged 65 years and older (from
8.7% in 1989 to 15.1% in 1999), as reported by
the Taiwanese Department of Health.4 This will
inflict an even greater burden on healthcare re-
sources since the cost of attending a patient with
diabetes is estimated to be 4.3 times greater than
that for a non-diabetic patient.5 Treatment of dia-
betes and its complications takes up 11.5% of
Taiwan’s total medical expenses.5
The Diabcare-Taiwan 2001 (DCT’01) study
was initiated within the larger framework of
the Diabcare-Asia 2001 project – a collaborative
study between Novo Nordisk Asia Pacific Pte Ltd
(Singapore) and nine participating Asian countries
working through their respective national diabe-
tes associations.6 The study marked Taiwan’s first
major endeavor to comprehensively evaluate
the healthcare status of patients with type 2 diabe-
tes at primary healthcare stations. The DCT’01
study was similar to the Diabcare-Asia (Taiwan)
1998 (DCT’98) study in design,7 except that the
DCT’01 study was carried out in the primary care
setting while the DCT’98 study was conducted in
secondary/tertiary care settings (medical centers
and district hospitals). The primary aim of this
study was to compare diabetes control, manage-
ment and complications in Taiwanese type 2
diabetes patients in the DCT’98 and DCT’01
studies, followed by an examination of the differ-
ences between elderly (* 65 years old) and non-
elderly groups.
Methods
Enrollment
Of the 312 primary healthcare stations located in
15 counties island-wide in Taiwan, 57 were ran-
domly selected. However, the six stations in Hua-
lien and Chiayi counties were excluded because
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Taipei Municipal Chung Hsing Hospital in Taipei
City. HbA1c analyses were performed by automatic
high-performance liquid chromatography (HPLC)
(Bio-Rad VARIANTTM, Bio-Rad Laboratories,
Hercules, CA, USA). The HPLC system was stan-
dardized against the Diabetes Control and Com-
plications Trial (DCCT) method.7
Type 1 diabetes was defined as primary diabe-
tes in a patient who required insulin therapy with-
in 1 year of diagnosis and continued this treatment
thereafter.8 All remaining patients with primary
diabetes were defined as having type 2 diabetes.
Secondary diabetes induced by drugs, pancreatic
disorders and so on was defined as diabetes other
than type 1 or type 2. Diabetic retinopathy was
diagnosed by ophthalmologists or detected by non-
mydriatic color fundus photography during rou-
tine screening as documented in the patients’
medical records. Advanced eye diseases included
neovascularization, retinal detachment and retinal
hemorrhage; legal blindness was defined as loss
of vision. Neuropathy was diagnosed based on
standard clinical examination and use of mono-
filaments. Foot complications included one or
more of the following: impalpable foot pulse,
healed ulcer, acute ulcer/gangrene, angioplasty/
bypass surgery.
Statistical analysis
All data were entered into SAS version 6.12
(SAS Institute Inc, Cary, NC, USA) by electronic
scanning (TELE form Elite, version 5.2, Cardiff
Software, San Macros, CA, USA). Data were vali-
dated by means of both the scanning software
and SAS.
Data were presented as mean ± standard devia-
tion (SD), range or percentage. When the data were
normally distributed, two-sample t test was used
to compare differences between two groups; the
chi-square test was used otherwise.
Multiple logistic regression analysis was per-
formed to investigate the relationship between the
binary outcome (presence or absence of a compli-
cation) and risk factors. All tests were two-sided,
and a p value of less than 0.05 was considered to
be significant.
Results
Among the 1339 primary care patients in the
DCT’01 study, 1302 had type 2 diabetes (97.2%),
27 had type 1 diabetes (2.0%) and 10 had other
types of diabetes (0.7%). The mean age of patients
with type 2 diabetes was 65.6 ± 9.7 years (Table
1), and there was a predominance of patients aged
* 65 years (60.3%) and females (66.2%).
Comparison between DCT’01 (primary care)
and DCT’98 (secondary/tertiary care)
Diabetes control, management and
complications
Compared with their secondary/tertiary care coun-
terparts, primary care type 2 diabetes patients were
older at the onset of diabetes (57.2 ± 10.3 vs. 52.1
± 11.1 years, p < 0.001), had a shorter duration of
diabetes (8.4 ± 5.9 vs. 10.3 ± 7.3 years, p < 0.001),
and a much smaller percentage received insulin
therapy (insulin only: 1.5% vs. 10.2%, p < 0.001;
combination of insulin and oral hypoglycemic
agent: 0.6% vs. 11.7%, p < 0.001). Despite having
worse HbA1c data (8.4 ± 1.8% vs. 8.1 ± 1.6%,
p < 0.001), primary care patients were generally
less extensively managed with fewer patients
performing home glucose monitoring (6.2% vs.
27.2%, p < 0.001) and more patients consuming
alcohol (9.6% vs. 7.0%, p = 0.008). Neverthe-
less, primary care patients still experienced lower
rates of complications, including kidney, retina,
leg, coronary and cerebrovascular diseases (Table
1).
Age * 65 and < 65 years
As illustrated in Table 2, primary care patients aged
* 65 years had a longer history (9.3 ± 6.5 vs. 7.2 ±
4.6 years, p < 0.001) and greater age at onset of
diabetes (62.7 ± 8.1 vs. 48.9 ± 7.4 years, p <
0.001), and tended to exercise more regularly
(56.5% vs. 47.2%, p = 0.005) than those aged < 65
years. Exercise was defined as regular if performed
* 3 times weekly for at least half an hour each time.
However, compared to their older (aged * 65 years)
counterparts, patients aged < 65 years had a signi-
ficantly higher mean body mass index (BMI)
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(25.9 ± 3.8 kg/m2 vs. 25.3 ± 3.6 kg/m2, p = 0.010)
and a higher percentage regularly consumed alco-
hol (13.5% vs. 7.0%, p < 0.001). These same
age-related trends were also found in patients in
secondary/tertiary care (data not shown). Less than
70% of primary care patients in both age groups
had fasting blood glucose and lipids checked in
the previous 3 months; however, more than 90%
of secondary/tertiary care patients had these items
checked during the same period of time.
Comparison of glycemic control by age groups
Compared to those aged * 65 years, primary care
patients aged < 65 years had significantly greater
elevation in metabolic parameters including HbA1c
(8.6 ± 1.8% vs. 8.2 ± 1.7%, p < 0.001), fasting
Table 1. Demographic and clinical characteristics of type 2 diabetes patients in the Diabcare-Asia
(Taiwan) (DCT) 1998 and DCT 2001 studies
DCT’98 DCT’01 p
Age (yr) < 0.001
n 2369 1302
Mean ± SD 62.2 ± 10.6 65.6 ± 9.7
Duration of diabetes (yr) < 0.001
n 2360 1277
Mean ± SD 10.3 ± 7.3 8.4 ± 5.9
Age at onset of diabetes (yr) < 0.001
n 2360 1277
Mean ± SD 52.1 ± 11.1 57.2 ± 10.3
BMI (kg/m2) 000.003
n 2349 1256
Mean ± SD 25.2 ± 3.6 25.5 ± 3.7
HbA1c (%) < 0.001
n 2024 1250
Mean ± SD 08.1 ± 1.6 08.4 ± 1.8
Smokers, n (%) 358 (15.3) 200 (15.7) 000.773
Alcohol consumption > 3 times/wk, n (%) 163 (7.0)0 121 (9.6)0 000.008
Complications, n (%)
Serum creatinine * 180 μmol/L 83 (4.2) 14 (1.6) < 0.001
Proteinuria * 30 mg/dL 599 (37.6) 251 (32.6) 0.020
Photocoagulation and/or advanced eye disease 248 (13.2) 64 (5.9) < 0.001
Retinopathy 570 (30.5) 104 (9.8)0 < 0.001
Foot complications* 214 (9.7)0 49 (4.0) < 0.001
MI/CABG/angioplasty 87 (3.7) 12 (1.0) < 0.001
Stroke 134 (5.7)0 51 (4.0) 0.027
ESRD 15 (0.6) 04 (0.3) 0.239
Leg amputation 23 (1.2) 05 (0.4) < 0.001
Home blood glucose monitoring, n (%) 600 (27.2) 77 (6.2) < 0.001
Type of treatment, n (%)
Insulin, no OHA 240 (10.2) 20 (1.5) < 0.001
Insulin and OHA 277 (11.7) 08 (0.6) < 0.001
OHA, no insulin 1806 (76.5)0 1238 (95.1)0 < 0.001
*Included one or coexistence of the following: impalpable foot pulse, healed ulcer and acute ulcer and/or angioplasty. BMI = body
mass index; CABG = coronary artery bypass graft; ESRD = end-stage renal disease; HbA1c = glycosylated hemoglobin; MI = myocardial
infarction; OHA = oral hypoglycemic agent; SD = standard deviation.
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plasma glucose (10.1 ± 3.4 mmol/L vs. 9.0 ± 3.1
mmol/L, p < 0.001), total cholesterol (5.4 ± 1.2 vs.
5.2 ± 1.1 mmol/L, p = 0.025), and triglyceride (2.0
± 1.2 mmol/L vs. 1.8 ± 1.1 mmol/L, p = 0.022)
(Table 2). These age-related profiles remained sim-
ilar in secondary/tertiary care patients, except for
triglyceride levels which showed no age-related
difference (data not shown). Consistent with the
mean HbA1c data, a significantly lower proportion
of primary care patients (9.4% vs. 14.0%, p <
0.05) in the < 65 years age group had optimal
glycemic control (HbA1c < 6.5%) as defined by the
Table 2. Demographic and clinical characteristics of type 2 diabetes patients aged < 65 years and
* 65 years in the Diabcare-Asia (Taiwan) (DCT) 2001 study
< 65 yr * 65 yr p
Duration of diabetes (yr) < 0.001
n 510 767
Mean ± SD 07.2 ± 4.6 09.3 ± 6.5
Age at onset of diabetes (yr) < 0.001
n 510 767
Mean ± SD 48.9 ± 7.4 62.7 ± 8.1
BMI (kg/m2) 0.010
n 495 761
Mean ± SD 25.9 ± 3.8 25.3 ± 3.6
HbA1c (%) < 0.001
n 501 749
Mean ± SD 08.6 ± 1.8 08.2 ± 1.7
Fasting blood glucose (mmol/L) < 0.001
n 357 502
Mean ± SD 10.1 ± 3.4 09.0 ± 3.1
Total cholesterol (mmol/L) 0.025
n 370 592
Mean ± SD 05.4 ± 1.2 05.2 ± 1.1
Triglyceride (mmol/L) 0.022
n 337 559
Mean ± SD 02.0 ± 1.2 01.8 ± 1.1
Lifestyle modification, n (%)
Smokers 083 (16.5) 117 (15.2) 0.529
Alcohol consumption > 3 times/wk 067 (13.5) 54 (7.0) < 0.001
Regular diet adherence 288 (56.4) 466 (60.4) 0.074
Regular exercise 237 (47.2) 435 (56.5) 0.005
Complications, n (%)
Serum creatinine * 180 μmol/L 10 (0.8) 04 (1.4) 0.583
Proteinuria * 30 mg/dL 090 (18.2) 161 (21.6) 0.873
Retinopathy* 51 (9.9) 099 (12.7) 0.106
Foot complications 15 (2.9) 37 (4.8) 0.096
MI/CABG/angioplasty 06 (1.2) 06 (0.8) 0.560
Stroke 10 (1.9) 41 (5.3) 0.003
ESRD 01 (0.2) 03 (0.4) 0.540
Neuropathy 061 (12.2) 093 (12.3) 0.957
*Including photocoagulation and/or advanced eye disease. BMI = body mass index; CABG = coronary artery bypass graft;
ESRD = end-stage renal disease; HbA1c = glycosylated hemoglobin; MI = myocardial infarction; SD = standard deviation.
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Asia-Pacific Type 2 Diabetes Policy Group.9 The
HbA1c profiles of patients in the DCT’98 study were
better than those of patients in the DCT’01 study,
for patients < 65 years (8.2 ± 1.7% vs. 8.6 ± 1.8%,
p < 0.001) and for patients * 65 years (7.9 ± 1.6%
vs. 8.2 ± 1.7%, p < 0.001) (Table 3).
Diabetes management and treatment
A significantly greater percentage of primary care
patients in the * 65 years age group had received
proteinuria checks (66.8% vs. 55.7%, p < 0.05),
eye examinations (57.0% vs. 46.0%, p < 0.05), and
foot examinations (39.3% vs. 26.9%, p < 0.05) in
the previous 6 months, as compared to those in
the < 65 years group. While the proportion of pa-
tients receiving the aforementioned examinations
was higher in secondary/tertiary care patients, this
difference was not significant (data not shown).
The most frequently prescribed oral hypogly-
cemic agents for patients in both age groups were
sulfonylureas and biguanides. Very few patients
received meglitinide, thiazolidinedione and _-
glucosidase inhibitor. There was no significant dif-
ference in the proportion of patients receiving in-
sulin therapy between the two age groups in either
the primary or the secondary/tertiary care settings.
Blood pressure control
As shown in Table 4, diabetic patients treated in a
primary care setting had better control of blood
pressure than those treated in a secondary/tertiary
setting (blood pressure * 140/90 mmHg, 42.3%
vs. 46.6%, p < 0.05). For the < 65 years age group,
patients in the DCT’98 study had poorer control
than those in the DCT’01 study (blood pressure *
140/90 mmHg, 44% vs. 37.5%, p < 0.05). Three
out of four patients (< 65 years and * 65 years:
74.1% vs. 75.9%, not significant) did not meet the
American Diabetes Association treatment target
for blood pressure (< 130/80 mmHg),10 and ap-
proximately two out of five (< 65 years and * 65
years: 37.5% vs. 45.4%, p < 0.05) had blood pres-
sure that exceeded the WHO/International Society
of Hypertension criteria for hypertension11 (* 140/
90 mmHg) (Table 4). Worryingly, a substantial
percentage of patients (16.0% in DCT’01 and
Table 3. Comparison of HbA1c profiles of type 2 diabetes
patients in the Diabcare-Asia (Taiwan) (DCT) 2001
and DCT 1998 studies by age group*
Age group HbA1c profile DCT’01 DCT’98 p
†
< 65 yr Mean ± SD 8.6 ± 1.8 8.2 ± 1.7
< 6.5% 009.4‡ 011.6§
6.5–7.5% 0 19.8 29.0
> 7.5% 70.9 59.4 < 0.001
* 65 yr Mean ± SD 8.2 ± 1.7 7.9 ± 1.6
< 6.5% 14.0 16.5
6.5–7.5% 0 24.7 32.1
> 7.5% 61.3 51.4 < 0.001
*Asia-Pacific Type 2 Diabetes Policy Group9; †p value indicates comparison of HbA1c
profile for respective age groups of DCT’01 and DCT’98 studies; ‡for DCT’01 study,
HbA1c profiles between patients < 65 yr vs. * 65 yr, p = 0.004; §for DCT’98 study,
HbA1c profiles between patients < 65 yr vs. * 65 yr, p < 0.001.
Table 4. Blood pressure control in type 2 diabetes patients in the Diabcare-Asia (Taiwan) (DCT) 2001
and DCT 1998 studies by age group
Blood pressure, n (%)
Study Age (yr) N
* 130/80 mmHg * 140/90 mmHg
DCT’01 < 65 0517 383 (74.1) 00194 (37.5)*
* 65 0784 595 (75.9) 0356 (45.4)
Total 1301 978 (75.2) 00550 (42.3)†
DCT’98 < 65 1296 985 (76.0) 00570 (44.0)*
* 65 1038 800 (77.1) 0518 (49.9)
Total 2334 1785 (76.5)0 1088 (46.6)†
*Blood pressure * 140/90 mmHg for those aged < 65 years, DCT’01 vs. DCT’98, 37.5% vs. 44.0%, p = 0.023; †blood pressure *
140/90 mmHg, DCT’01 vs. DCT’98, 42.3% vs. 46.6%, p = 0.012. N = number of patients available for analysis.
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19.0% in DCT’98, p < 0.05) with high blood pres-
sure (* 140/90mmHg) were not taking any anti-
hypertensive agent. Calcium antagonists were the
most commonly used medications for hyperten-
sion, followed by angiotensin-converting enzyme
inhibitors, beta-blockers and diuretics. Among
those treated with antihypertensive agents whose
blood pressure remained high, 57.9% took only
one drug and 88.0% took two or fewer drugs.
Diabetes complications
In the primary care setting, patients in the * 65
years group had a higher frequency of foot com-
plications (4.8% vs. 2.9%, p = 0.096) and a greater
percentage of stroke (5.3% vs. 1.9%, p = 0.003)
than those in the < 65 years group (Table 2). In
the secondary/tertiary care setting, patients * 65
years showed a significantly higher prevalence of
myocardial infarction/coronary artery bypass graft/
angioplasty (5.5% vs. 2.3%, p < 0.05) and stroke
(7.0% vs. 4.7%, p < 0.05) than the < 65 years group.
As detailed in Table 5, multiple logistic regres-
sion analysis of patients treated in primary care
revealed that hypertension was the borderline risk
factor for stroke (OR, 4.17; 95% CI, 0.91–19.23;
p = 0.066). Significant risk factors for cataract were
age at diabetes onset (OR, 1.11; 95% CI, 1.06–
1.16; p < 0.001), duration of diabetes (OR, 1.15;
95% CI, 1.09–1.21; p < 0.001), gender (OR, 1.54;
95% CI, 1.00–2.37; p = 0.052) and triglyceride (OR,
1.23; 95% CI, 1.01–1.50; p = 0.039). Risk factors
for retinopathy were duration of diabetes (OR,
1.16; 95% CI, 1.08–1.25; p < 0.001) and total cho-
lesterol (OR, 0.68; 95% CI, 0.48–0.96; p = 0.030).
Risk factors for foot complications were age at
diabetes onset (OR, 1.12; 95% CI, 1.01–1.23; p =
0.029) and diabetes duration (OR, 1.20; 95% CI,
1.06–1.35; p = 0.003). The risk factor for protein-
uria was diabetes duration (OR, 1.07; 95% CI,
1.02–1.13; p = 0.012).
Table 6 shows the risk factors for each compli-
cation in the DCT’98 study. Similar to the results
of the DCT’01 study, duration of diabetes emerged
as a risk factor for cataract, retinopathy, foot com-
plications and proteinuria. The striking difference
in risk factor profile might be attributable to the
fact that total cholesterol, while being a risk factor
for retinopathy, foot complications and proteinu-
ria in the DCT ’98 study, showed only significant
relation to retinopathy in the DCT’01 study; and
hypertension as a risk factor for stroke, cataract,
retinopathy and proteinuria in the DCT’98 study
became barely significant for these complications
in the DCT’01 study (Tables 5 and 6).
Discussion
Due to the lack of an orthodox system of family
physicians in Taiwan, patients can visit a hospital
directly without referral from general practitioners.
However, as Table 1 indicates, compared with those
treated in a secondary/tertiary care setting, patients
with type 2 diabetes treated in a primary care set-
ting had less severe diabetes as reflected by shorter
duration, older age at onset, and fewer complica-
tions. Medical intervention, including both medi-
cal treatment and lifestyle modification, was less
extensive in the primary care setting where the pro-
portion of patients receiving insulin injections was
much lower (Table 1). This situation might explain
the slightly higher mean HbA1c level of primary
care patients compared to that of secondary/terti-
ary care patients. The shortage of well-trained staff
and adequate resources for diabetes management
at the primary care level may be a contributing fac-
tor to this result.12 Reluctance of patients to receive
insulin injections, and lack of familiarity of pri-
mary care physicians in prescribing insulin or man-
aging insulin-treated patients might play a major
role in the lower rate of insulin injections, although
less severe disease status may also be important.
More emphasis should be placed on medical edu-
cation for primary care physicians and patients.
Training in insulin administration and the impor-
tance of home glucose monitoring are particularly
needed.
While nearly all patients treated in a second-
ary/tertiary care setting had HbA1c data, less than
one fourth of primary care patients had the same
data, indicating HbA1c testing that was even lower
than the 32% examination rate of patients enrolled
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Table 5. Individual risk factors for each complication in the Diabcare-Asia (Taiwan) (DCT) 2001 study
Variable Stroke Cataract Retinopathy Foot complications Proteinuria
Age
OR 1.66 1.0 0.46 0.44 0.59
95% CI 0.27, 10.27 0.49, 2.04 0.14, 1.49 0.06, 3.05 0.27, 1.32
p 0.587 0.992 0.195 0.403 0.202
Age at DM onset
OR 1.00 1.11 1.06 1.12 1.01
95% CI 0.92, 1.10 1.06, 1.16 1.0, 1.13 1.01, 1.23 0.97, 1.06
p 0.936 < 0.001* 0.063 0.029* 0.566
Duration of DM
OR 1.04 1.15 1.16 1.20 1.07
95% CI 0.93, 1.16 1.09, 1.21 1.08, 1.25 1.06, 1.35 1.02, 1.13
p 0.505 < 0.001* < 0.001* 0.003* 0.012*
Gender
OR 0.48 1.54 0.75 0.49 0.88
95% CI 0.17, 1.33 1.0, 2.37 0.38, 1.49 0.17, 1.40 0.53, 1.45
p 0.157 0.052 0.414 0.179 0.611
BMI
OR 1.09 1.01 1.00 1.01 1.03
95% CI 0.97, 1.23 0.96,1.07 0.92, 1.09 0.87, 1.17 0.97, 1.09
p 0.165 0.605 0.965 0.901 0.394
HbA1c
OR 0.80 1.03 0.99 0.93 1.14
95% CI 0.55, 1.16 0.89, 1.18 0.80, 1.22 0.65, 1.34 0.98, 1.33
p 0.238 0.725 0.907 0.712 0.100
Fasting blood glucose
OR 1.07 0.95 1.10 1.06 1.02
95% CI 0.89, 1.28 0.88, 1.03 0.98, 1.24 0.89, 1.25 0.94, 1.10
p 0.462 0.201 0.113 0.522 0.660
Total cholesterol
OR 1.12 1.06 0.68 1.50 1.09
95% CI 0.72, 1.75 0.88, 1.28 0.48, 0.96 0.99, 2.27 0.88, 1.35
p 0.622 0.540 0.030* 0.055 0.445
Triglyceride
OR 1.01 1.23 1.03 1.13 1.12
95% CI 0.63, 1.61 1.01, 1.50 0.74, 1.43 0.71, 1.79 0.90, 1.39
p 0.967 0.039* 0.859 0.608 0.308
Hypertension
OR 4.17 0.84 1.99 1.51 1.60
95% CI 0.91, 19.23 0.55, 1.31 0.93, 4.26 0.45, 5.10 0.94, 2.72
p 0.066 0.447 0.077 0.504 0.086
*Statistical significance at the 5% level. BMI = body mass index; CI = confidence interval; DM = diabetes mellitus; HbA1c = glycosylated
hemoglobin; OR = odds ratio.
For the “age” variable, odds ratio was expressed as the relative risk of complication for patients * 65 years vs. those < 65 years;
for the “gender” variable, females vs. males; for the “hypertension” variable, patients with hypertension vs. patients with no hypertension;
for the “proteinuria” complication, patients with urinary protein excretion * 30 mg/dL vs. patients with no proteinuria.
For the continuous variables (age at DM onset, duration of DM, BMI, HbA1c, fasting blood glucose, total cholesterol, triglyceride),
the odds ratio indicates risk for every 1 unit increase (e.g. an odds ratio for triglyceride of 1.2 implies a 20% increase in risk for
every 1 mmol/L increase in triglyceride).
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Table 6. Individual risk factors for each complication in the Diabcare-Asia (Taiwan) (DCT) 1998 study
Variable Stroke Cataract Retinopathy Foot complications Proteinuria
Age
OR 0.66 1.14 0.76 0.60 1.08
95% CI 0.33, 1.34 0.75, 1.72 0.50, 1.14 0.34, 1.05 0.71, 1.64
p 0.254 0.537 0.178 0.075 0.727
Age at DM onset
OR 1.05 1.10 1.0 1.02 1.01
95% CI 1.01, 1.09 1.07, 1.13 0.98, 1.02 0.99, 1.04 0.98, 1.03
p 0.009* < 0.001* 0.750 0.266 0.634
Duration of DM
OR 1.03 1.11 1.06 1.04 1.04
95% CI 0.99, 1.08 1.09, 1.15 1.04, 1.09 1.01, 1.08 1.01, 1.07
p 0.147 < 0.001* < 0.001* 0.012* 0.004*
Gender
OR 1.11 1.09 0.89 0.86 0.66
95% CI 0.72, 1.71 0.85, 1.41 0.69, 1.15 0.60, 1.22 0.51, 0.86
p 0.635 0.490 0.380 0.394 0.002*
BMI
OR 0.95 0.98 0.99 0.97 1.05
95% CI 0.90, 1.01 0.94, 1.01 0.96, 1.03 0.93, 1.02 1.01, 1.09
p 0.118 0.230 0.688 0.267 0.011*
HbA1c
OR 1.16 1.09 1.14 1.08 1.10
95% CI 1.003, 1.345 0.99, 1.19 1.04, 1.24 0.96, 1.21 1.00, 1.21
p 0.046* 0.073 0.005* 0.222 0.049*
Fasting blood glucose
OR 0.98 0.97 1.0 1.04 1.0
95% CI 0.91, 1.06 0.93, 1.02 0.96, 1.05 0.98, 1.10 0.95, 1.05
p 0.648 0.265 0.851 0.249 0.947
Total cholesterol
OR 0.85 1.0 1.24 1.18* 1.26
95% CI 0.69, 1.05 0.88, 1.13 1.10, 1.40 1.00, 1.39 1.11, 1.43
p 0.127 0.989 < 0.001* 0.046* < 0.001*
Triglyceride
OR 1.12 1.12 0.99 1.03 1.35
95% CI 0.94, 1.33 1.00, 1.26 0.89, 1.11 0.89, 1.20 1.20, 1.52
p 0.201 0.047* 0.900 0.660 < 0.001*
Hypertension
OR 3.19 1.44 1.65 1.45 1.93
95% CI 1.79, 5.71 1.10, 1.89 1.24, 2.18 0.97, 2.14 1.45, 2.57
p < 0.001* 0.009* < 0.001* 0.071 < 0.001*
*Statistical significance at the 5% level. BMI = body mass index; CI = confidence interval; DM = diabetes mellitus; HbA1c = glycosylated
hemoglobin; OR = odds ratio.
in the Diabcare-Asia 2001 study.6 The lack of re-
imbursement for HbA1c testing from the National
Health Insurance System of Taiwan seems one
likely explanation. The level of glycemic control
was unsatisfactory in this study, with only 9.4% of
patients < 65 years and 14.0% of patients * 65 years
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having HbA1c values within the optimal range de-
fined by the Asia-Pacific Type 2 Diabetes Policy
Group (HbA1c < 6.5%).
9 The respective figures ob-
tained from patients in the Diabcare-Asia 1998
study were also low (11.6% and 16.0%). Mirror-
ing worldwide trends, the overall glycemic control
of our patients in both primary and secondary/
tertiary care was inadequate. Several landmark
studies have pointed to the importance of tight
glycemic control.13,14 Better glycemic control may
reduce the need for more intensive care of diabetic
complications later, helping to facilitate a decrease
in healthcare costs as a whole. There is also evi-
dence indicating that sustained reduction in HbA1c
level among adult diabetic patients can lead to
significant cost savings within 1–2 years of im-
provement.15
The rates of screening for eye and kidney com-
plications among patients treated in a primary care
setting were comparable to those for all patients
in the Diabcare-Asia 2001 study, while the screen-
ing rate for foot complications was lower than in
Diabcare-Asia 2001. The screening rates for the
abovementioned complications were slightly
better than those for female African Americans in
primary care.16
Several studies have suggested that earlier on-
set of diabetes,17 longer duration of diabetes,17–19
female gender18,19,20–25 and hypertriglyceride-
mia26–28 are risk factors for cataract, a finding that
was also reflected in our primary care patients
(Table 5). Similar risk factors for cataract were
found in secondary/tertiary care patients in our
previous study, except an additional association
with hypertension and a negative association with
female gender (Table 6). No known mechanism
provides an explanation for the excess risk of
cataract in female diabetic subjects.24 In a cross-
sectional study, patients undergoing surgery for
posterior capsule cataract had a significantly high-
er average concentration of fasting serum trigly-
cerides.26 Elevated triglycerides were associated with
increased risk of posterior subcapsule cataract in
men but not in women.28 However, this is not a
readily apparent explanation for how triglycerides
might affect cataract development, despite the fact
that a close association was found in both primary
and secondary/tertiary care settings. In contrast to
the normal subjects, we found no significant im-
pact of age on the prevalence of cataract. This
may be related to the more important role of age
at diabetes onset and duration of diabetes (Tables
5 and 6).
As Tables 5 and 6 reveal, patients with a longer
duration of diabetes also had a significantly
higher prevalence of cataract, retinopathy, foot
complications and proteinuria. Previous studies
also found that hypertension was a significant
risk factor for stroke,29–32 retinopathy33 and protein-
uria.34–36
As in much previous research, our study of dia-
betes patients treated in a secondary/tertiary care
setting also found that male type 2 diabetics were
more susceptible to renal complications (Table
6).37–40 However, a negative association of renal
complications with gender, similar to that found
in primary care patients in this study, has also
been reported.41 Further studies are needed to ex-
plain the reasons for this discrepancy.
The most striking difference in the risk factors
related to diabetic complications between the
DCT’01 and DCT’98 (Tables 5 and 6) studies was
that a close association of higher serum cholester-
ol levels with foot complications and proteinuria
was found in patients treated in a secondary/terti-
ary care setting but not in patients treated in a pri-
mary care setting. High serum cholesterol or
hyperlipidemia have been associated with micro-
albuminuria42 or renal disorders.36,38,43 However,
the association of higher serum cholesterol with
retinopathy in this study contradicts the findings
of a previous study.44
Hypertension is a risk factor for nephropathy
in normal subjects34,35 and in subjects with type 2
diabetes.36 The importance of maintaining an op-
timum blood pressure of ) 130/80 mmHg and at
least a normal blood pressure of ) 140/90 mmHg
is well-established management of diabetes. This
study demonstrated poor rates of blood pressure
control in type 2 diabetes patients treated in both
primary and secondary/ tertiary care settings (Table
4). The most commonly used antihypertensive
115J Formos Med Assoc | 2006 • Vol 105 • No 2
Primary care for diabetes in Taiwan
agent was calcium-channel blockers in primary
care patients and angiotensin-converting enzyme
inhibitors in secondary/tertiary care patients. More
attention is needed to provide adequate antihyper-
tensive treatment for Taiwanese patients. Moreover,
as the UK Prospective Diabetes Study Group has
shown, tight control of blood pressure is associat-
ed with reduced risk of stroke and microvascular
diseases.33 Further study of the importance of blood
pressure control in Taiwanese diabetic patients is
required.
The major limitations of our study are that some
data on diabetic complications were self-reported
by patients or obtained from chart review, and
comprehensive, centralized laboratory examina-
tions were not performed. While HbA1c was a risk
factor for stroke, retinopathy and proteinuria in
the DCT’98 study (Table 6), it had no relation to
any complication in the DCT’01 study (Table 5).
Therefore, care must be taken in generalizing the
findings. This may have been related to the use of
a cross-sectioned design, retrospective recording of
laboratory data except for HbA1c, and incomplete
collection of various data, such as for retinopathy
and proteinuria.
In conclusion, diabetes control was poorer
among patients treated in primary care than in sec-
ondary/tertiary care, while blood pressure control
was better in primary care. Similar diabetes con-
trol and clinical features existed in patients aged
< 65 years and * 65 years in both care settings. The
shorter duration of diabetes and better control of
blood pressure in primary care patients and in
patients aged < 65 years as compared with their
respective counterparts might be related to the
lower prevalence of complications. A high percent-
age of patients in both care settings had inadequate
glycemic and blood pressure control.
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